Personalized colistin dosing for premature infants
Part of Infections clinical trials.
This trial is testing a way to give the antibiotic colistin (which fights hard-to-treat infections) more personally to premature newborns, based on each baby's own body. The goal is to make the treatment safer and more effective for babies who are very sick in the neonatal intensive care unit (NICU).
Summary written for real people, not researchers, by Clin2.
Who can take part
- The baby was born more than 3 weeks early (before 37 weeks of pregnancy)
- The baby is less than 1 month old (under 30 days)
- The baby has a hospital-acquired infection that is resistant to standard antibiotics
- The baby has already started colistin and has been taking it for at least 2 days
- The baby has healthy kidneys and is not taking other medications that could harm the kidneys
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking alpha lipoic acid (an antioxidant) alongside the antibiotic colistin can help protect the kidneys from damage. It may be helpful for patients who need colistin to fight a serious bacterial infection.
This study tests different ways of giving the antibiotic colistin to patients in the ICU with infections that are hard to treat. The goal is to find the best dosing schedule to help you fight the infection more effectively.
This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.
This trial tests whether giving a nebulized (inhaled) antibiotic called colistimethate sodium can prevent ventilator-associated pneumonia (a lung infection) in children who are on a breathing machine. If it works, this could reduce the risk of serious lung infections in hospitalized children.
This trial tests a personalized dosing approach for certain antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, and meropenem) in hospitalized children with serious infections. The goal is to adjust the dose based on blood tests to make sure each child gets the right amount of medicine.
This trial tests if inhaling a medication called colistin can prevent ventilator-associated pneumonia (a lung infection) in patients who are on a breathing machine. It aims to reduce the risk for those at high risk of getting an infection from drug-resistant bacteria.
Hear when a new Colistin Adverse Reaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.